PURE Bioscience (OTCMKTS:PURE) Sees Large Decline in Short Interest

PURE Bioscience (OTCMKTS:PURE) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 3,865 shares, a decrease of 65.0% from the June 30th total of 11,031 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 68,596 shares, the days-to-cover ratio is presently 0.1 days.

PURE Bioscience Price Performance

Shares of PURE stock remained flat at $0.07 during trading hours on Tuesday. 27,536 shares of the stock traded hands, compared to its average volume of 32,177. The firm has a market capitalization of $9.09 million, a PE ratio of -2.33 and a beta of 0.22. The business’s fifty day moving average is $0.07 and its two-hundred day moving average is $0.07. PURE Bioscience has a 52-week low of $0.04 and a 52-week high of $0.14.

PURE Bioscience (OTCMKTS:PURE) last posted its quarterly earnings data on Monday, June 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.51 million during the quarter.

About PURE Bioscience

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.